1-20 of 28
David M. Hyman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P4-08-02: LOXO-783: A potent, highly mutant selective and brain-penetrant allosteric PI3Kα H1047R inhibitor in combination with standard of care (SOC) treatments in preclinical PI3Kα H1047R-mutant breast cancer models

Free
Loredana Puca, Michele S. Dowless, Carmen M. Perez-Ferreiro, Maria Jesus Ortiz-Ruiz, Gregory P. Donoho, Andrew Capen, Lysiane Huber, Sarah M. Bogner, Dongling Fei, Jason R. Manro, Chun Ping Yu, Wei Guo Xu, Rui Wang, Shuang Chen, Mark A. Hicks, Parisa Zolfaghari, Andrew Faber, Raymond Gilmour, Monica D. Ramstetter, Matthew T. Chang, Maria Jose Lallena, Xuequian Gong, David M. Hyman, Lillian M. Smyth, Barbara J. Brandhuber, Barry S. Taylor, Anke Klippel
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P4-08-02.
https://doi.org/10.1158/1538-7445.SABCS22-P4-08-02
Published: 01 March 2023
View articletitled, Abstract P4-08-02: LOXO-783: A potent, highly mutant selective and brain-penetrant allosteric PI3Kα H1047R inhibitor in combination with standard of care (SOC) treatments in preclinical PI3Kα H1047R-mutant breast cancer models
Journal Articles

Abstract 5680: TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors

Free
Emiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, Alison M. Schram, Helen H. Won, Sophie Shifman, Amanda Kulick, Laura Baldino, Eneda Toska, Sabrina Arena, Benedetta Mussolin, Ram Kannan, Neil Vasan, Alexander N. Gorelick, Michael F. Berger, Yi Liao, Uwe Rix, Alberto Bardelli, Jacklyn Hechtman, Elisa de Stanchina, David M. Hyman, Chandra Verma, Andrea Ventura, Alexander Drilon, Maurizio Scaltriti
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5680.
https://doi.org/10.1158/1538-7445.AM2020-5680
Published: 15 August 2020
View articletitled, Abstract 5680: TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
Journal Articles

Abstract 709: The utility of plasma ctDNA for detection of KRAS G12C and other mutations in lung cancers

Free
Yonina R. Murciano-Goroff, Kathryn C. Arbour, Michael D. Offin, Hai-Yan Y. Tu, Emily S. Lebow, Tristan S. Shaffer, Caterina Bertucci, Syed A. Hosseini, Kavita Garg, Lee P. Lim, Mark Li, Jason C. Chang, Jorge S. Reis-Filho, Pedram Razavi, James M. Isbell, Gregory J. Riely, David M. Hyman, Piro Lito, Bob T. Li
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 709.
https://doi.org/10.1158/1538-7445.AM2020-709
Published: 15 August 2020
View articletitled, Abstract 709: The utility of plasma ctDNA for detection of KRAS G12C and other mutations in lung cancers
Journal Articles

Abstract 5280: Kinase fusions drive endocrine resistance in estrogen receptor-positive breast cancer

Free
Bo Liu, Dara S. Ross, Alison M. Schram, Pedram Razavi, Stephen M. Lagana, Yanming Zhang, Maurizio Scaltriti, Jacqueline F. Bromberg, Marc Ladanyi, David M. Hyman, Alexander Drilon, Ahmet Zahir, Ryma Benayed, Jaclyn F. Hechtman, Sarat Chandarlapaty
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5280.
https://doi.org/10.1158/1538-7445.AM2020-5280
Published: 15 August 2020
View articletitled, Abstract 5280: Kinase fusions drive endocrine resistance in estrogen receptor-positive breast cancer
Journal Articles

Abstract P1-19-05: Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer

Free
Lillian M Smyth, Gerald Batist, Funda Meric-Bernstam, Peter Kabos, Iben Spanggaard, Ana Lluch, Alison Schram, Andrea Varga, Andrea Wong, Helen Ambrose, Alan Barnicle, T. Hedley Carr, Elza C de Bruin, Carolina Salinas-Souza, Andrew Foxley, Joana Hauser, Justin PO Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Martine Roudier, Gaia Schiavon, Pedram Razavi, Udai Banerji, Sarat Chandarlapaty, José Baselga, David M Hyman
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P1-19-05.
https://doi.org/10.1158/1538-7445.SABCS19-P1-19-05
Published: 15 February 2020
View articletitled, Abstract P1-19-05: Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer
Journal Articles

Abstract P1-19-08: Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT ‘basket’ trial

Free
Hans Wildiers, Valentina Boni, Cristina Saura, Mafalda Oliveira, Komal Jhaveri, Helen Won, François-Clément Bidard, Adam M Brufsky, Mark E Burkard, Andrés Cervantes, Carlos Fernández-Martos, Barbara Haley, Sherene Loi, Iben Spanggaard, Stefano Panni, Janice Lu, Melanie E Dujka, Feng Xu, Sonia Macia, Lisa D Eli, Alshad S Lalani, Sarina Piha-Paul, Funda Meric-Bernstam, David B Solit, David M Hyman
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P1-19-08.
https://doi.org/10.1158/1538-7445.SABCS19-P1-19-08
Published: 15 February 2020
View articletitled, Abstract P1-19-08: Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT ‘basket’ trial
Journal Articles

Abstract 729: Zygosity, lineage, and penetrance dictate the role of germline pathogenicity in tumorigenesis

Free
Chaitanya Bandlamudi, Preethi Srinivasan, Philip Jonsson, Yelena M. Kemel, Shweta S. Chavan, Allison L. Richards, Alex Penson, Craig M. Bielski, Chris Fong, Aijazuddin Syed, Gowtham Jayakumaran, Meera Prasad, Jason Hwee, Nikolaus Schultz, Semanti Mukherjee, Vijai Joseph, Diana Mandelkar, Ozge Birsoy, Liying Zhang, Jinru Shia, Ahmet Zehir, Marc Ladanyi, David M. Hyman, Kenneth Offit, Mark E. Robson, David B. Solit, Zsofia K. Stadler, Michael F. Berger, Barry S. Taylor
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 729.
https://doi.org/10.1158/1538-7445.AM2019-729
Published: 01 July 2019
View articletitled, Abstract 729: Zygosity, lineage, and penetrance dictate the role of germline pathogenicity in tumorigenesis
Journal Articles

Abstract LB-118: Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation

Free
Emiliano Cocco, Amanda Kulick, Sandra Misale, Rona Yaeger, Pedram Razavi, Helen H. Won, Ryan Ptashkin, Jaclyn F. Hechtman, Eneda Toska, James Cownie, Romel Somwar, Sophie Shifman, Marissa Mattar, S Duygu Selçuklu, Aliaksandra Samoila, Sean Guzman, Brian B. Tuch, Kevin Ebata, Elisa de Stanchina, Rebecca J. Nagy, Richard B. Lanman, Michael F. Berger, Marc Ladanyi, David M. Hyman, Alexander Drilon, Maurizio Scaltriti, Alison M. Schram
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): LB-118.
https://doi.org/10.1158/1538-7445.AM2019-LB-118
Published: 01 July 2019
View articletitled, Abstract LB-118: Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation
Journal Articles

Abstract 929: Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial

Free
Helen H. Won, S. Duygu Selcuklu, Sarina A. Piha-Paul, Cristina Saura, Jordi Rodon, Ingrid A. Mayer, Sherene Loi, Geoffrey I. Shapiro, Janice Lu, Adam Brufsky, Catherine Zimel, Myra Melcer, Maurizio Scaltriti, Lisa D. Eli, Richard E. Cutler, Jr., Alshad S. Lalani, Richard P. Bryce, Carlos Arteaga, Funda Meric-Bernstam, Michael F. Berger, David B. Solit, Alison Schram, David M. Hyman
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 929.
https://doi.org/10.1158/1538-7445.AM2019-929
Published: 01 July 2019
View articletitled, Abstract 929: Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial
Journal Articles

Abstract CT014: Initial results from the Phase I study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors

Free
Alison Schram, Anna Spreafico, Marc Oliva, Irene Brana, Elena Garralda, Nehal Lakhani, Daniel Von Hoff, Erkut Borazanci, Naimish Pandya, Kimberly Hoffman, Robin Hallett, Patricia Giblin, Judit Anido, Adrianne Kelly, Robert Wasserman, Joan Seoane, Lillian Siu, David M. Hyman, Josep Tabernero
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT014.
https://doi.org/10.1158/1538-7445.AM2019-CT014
Published: 01 July 2019
View articletitled, Abstract CT014: Initial results from the Phase I study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors
Journal Articles

Abstract 1681: Prospective clinical sequencing distinguishes independent primary cancers from recurrent or metastatic disease

Free
Alison M. Schram, Chai Bandlamudi, Ahmet Zehir, Marc Ladanyi, Michael F. Berger, Barry S. Taylor, David M. Hyman
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1681.
https://doi.org/10.1158/1538-7445.AM2019-1681
Published: 01 July 2019
View articletitled, Abstract 1681: Prospective clinical sequencing distinguishes independent primary cancers from recurrent or metastatic disease
Journal Articles

Abstract 1752: BRCA-mediated tumorigenesis is origin and cell-type dependent

Free
Philip Jonsson, Michael L. Cheng, Chaitanya Bandlamudi, Preethi Srinivasan, Shweta S. Chavan, Noah D. Friedman, Ezra Y. Rosen, Allison L. Richards, Nancy Bouvier, S. Duygu Selcuklu, Craig Bielski, Wassim Abida, Ahmet Zehir, Nikolaus Schultz, Mark T. Donoghue, Jose Baselga, Kenneth Offit, Marc Ladanyi, Eileen M. O’Reilly, Howard I. Scher, Zsofia K. Stadler, Mark E. Robson, David M. Hyman, Michael F. Berger, David B. Solit, Barry S. Taylor
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1752.
https://doi.org/10.1158/1538-7445.AM2019-1752
Published: 01 July 2019
View articletitled, Abstract 1752: BRCA-mediated tumorigenesis is origin and cell-type dependent
Journal Articles

Abstract 2934: AKT mutant allele-specific activation dictates pharmacologic sensitivities

Free
Tripti Shrestha Bhattarai, Tambudzai Shamu, Swati Patel, Alexander Gorelick, Matthew T. Chang, Elena I. Gavrila, JianJong Gao, Mark T. Donoghue, Paul S. Gao, Tara Soumerai, Wassim Abida, Lilian M. Smyth, David M. Hyman, David B. Solit, Barry S. Taylor
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2934.
https://doi.org/10.1158/1538-7445.AM2019-2934
Published: 01 July 2019
View articletitled, Abstract 2934: AKT mutant allele-specific activation dictates pharmacologic sensitivities
Journal Articles

Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions

Free
Emiliano Cocco, Jamal Benhamida, Sumit Middha, Ahmet Zehir, Kerry Mullaney, Jinru Shia, Rona Yaeger, Liying Zhang, Donna Wong, Liliana Villafania, Khedoudja Nafa, Maurizio Scaltriti, Alexander Drilon, Leonard Saltz, Alison M. Schram, Zsofia K. Stadler, David M. Hyman, Ryma Benayed, Marc Ladanyi, Jaclyn F. Hechtman
Journal: Cancer Research
Cancer Res (2019) 79 (6): 1047–1053.
https://doi.org/10.1158/0008-5472.CAN-18-3126
Published: 15 March 2019
View articletitled, Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions
Open the PDF for Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions in another window
Journal Articles

Abstract 5533: Cell-free DNA sequencing in ERBB2-mutant breast cancer patients treated with neratinib and fulvestrant: Exploratory analysis from the Phase 2 SUMMIT ‘basket' trial

Free
Alison M. Schram, S. Duygu Selcuklu, Rebecca J. Nagy, Lillian M. Smyth, Lisa D. Eli, Richard E. Cutler, Alshad S. Lalani, David M. Hyman, Richard B. Lanman
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 5533.
https://doi.org/10.1158/1538-7445.AM2018-5533
Published: 01 July 2018
View articletitled, Abstract 5533: Cell-free DNA sequencing in ERBB2-mutant breast cancer patients treated with neratinib and fulvestrant: Exploratory analysis from the Phase 2 SUMMIT ‘basket' trial
Journal Articles

Abstract CT011: First in human study of activin-A inhibitor, STM434, in patients with granulosa cell ovarian cancer and other advanced solid tumors

Free
Jessica J. Tao, Joyce F. Liu, Drew W. Rasco, Willis Navarro, Christopher M. Haqq, David M. Hyman
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT011.
https://doi.org/10.1158/1538-7445.AM2018-CT011
Published: 01 July 2018
View articletitled, Abstract CT011: First in human study of activin-A inhibitor, STM434, in patients with granulosa cell ovarian cancer and other advanced solid tumors
Journal Articles

Abstract CT020: Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in treatment of patients with advanced mesothelioma

Free
Marjorie G. Zauderer, David M. Hyman, Evan W. Alley, Johanna C. Bendell, Silvia Novello, Todd M. Bauer, Axel-Rainer Hanauske, Anna M. Szpurka, Suhyun Kang, Anindya Chatterjee, Volker Wacheck, Patrick Brueck, Anna M. Varghese
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT020.
https://doi.org/10.1158/1538-7445.AM2018-CT020
Published: 01 July 2018
View articletitled, Abstract CT020: Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in treatment of patients with advanced mesothelioma
Journal Articles

Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition

Free
Rona Yaeger, Zhan Yao, David M. Hyman, Jaclyn F. Hechtman, Efsevia Vakiani, HuiYong Zhao, Wenjing Su, Lu Wang, Andrew Joelson, Andrea Cercek, Jose Baselga, Elisa de Stanchina, Leonard Saltz, Michael F. Berger, David B. Solit, Neal Rosen
Journal: Cancer Research
Cancer Res (2017) 77 (23): 6513–6523.
https://doi.org/10.1158/0008-5472.CAN-17-0768
Published: 30 November 2017
View articletitled, Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition
Open the PDF for Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition in another window
Includes: Supplementary data
Journal Articles

Abstract 4380: Integrative genomics analysis of metastatic colorectal cancer

Free
Marla Lipsyc, Walid Chatila, Jaclyn F. Hechtman, Francisco Sanchez-Vega, Sumit Middha, Andrea Cercek, Zsofia Stadler, Ritika Kundra, Aijazuddin Syed, David M. Hyman, Ahmet Zehir, Armin Shahrokni, Anna Varghese, Diane Reidy, Neil H. Segal, Efsevia Vakiani, David B. Solit, Marc Ladanyi, Michael F. Berger, Nancy Kemeny, Leonard Saltz, Nikolaus Schultz, Rona Yaeger
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4380.
https://doi.org/10.1158/1538-7445.AM2017-4380
Published: 01 July 2017
View articletitled, Abstract 4380: Integrative genomics analysis of metastatic colorectal cancer
Journal Articles

Abstract CT003: Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma

Free
Ryan J. Sullivan, Filip Janku, Bob T. Li, Deborah Wong, Jeffrey Sosman, Vicki Keedy, Elizabeth Buchbinder, Anthony Tolcher, Anna Varghese, David M. Hyman, Keith T. Flaherty, Antoni Ribas, Richard Carvajal, Andrea Wang-Gillam, Harriet Kluger, Manish Patel, Peter Langecker, Mary Varterasian, Dean Welsch, Jeffrey Infante
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT003.
https://doi.org/10.1158/1538-7445.AM2017-CT003
Published: 01 July 2017
View articletitled, Abstract CT003: Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma